Revance Therapeutics, Inc. (RVNC) on Monday announced a proposed public offering of $100 million of shares.
The drug maker expects to grant the underwriters a 30-day option to purchase additional shares in an amount not to exceed 15 percent of the number of shares offered in the public offering.
The company intends to use the net proceeds from the offering to support the commercial growth of its aesthetics portfolio, including Daxxify and the RHA Collection of dermal fillers, to support the launch of Daxxify into the therapeutics market.
Revance also plans to use the net proceeds for working capital, research and development, and general corporate purposes.
Barclays is working as the sole book-running manager for the proposed offering.
RVNC was trading down by 8.31 percent at $6.40 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.